- Home
- CYCU vs CELZ Comparison
CYCU vs CELZ Comparison
Compare CYCU & CELZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CYCU | CELZ |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | United States | United States |
| Employees | 74 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 7.8M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | CYCU | CELZ |
|---|---|---|
| Price | $0.63 | $2.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 602.4K | 60.6K |
| Earning Date | 06-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,000.00 |
| Revenue This Year | $8.92 | N/A |
| Revenue Next Year | $10.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.16 | $1.50 |
| 52 Week High | $7.13 | $6.25 |
Technical Indicators
Market Signals| Indicator | CYCU | CELZ |
|---|---|---|
| Relative Strength Index (RSI) | 34.56 | 38.77 |
| Support Level | $0.58 | $1.74 |
| Resistance Level | $1.05 | $1.99 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 10.58 | 10.53 |
Price Performance
Historical ComparisonAbout CYCU Cycurion Inc.
Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).
About CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.